Together, we can end viral hepatitis.

We are the only grant-making organization dedicated exclusively to the mission of ending viral hepatitis.

By funding a variety of the most effective activities, EndHep2030 intends to overcome the barriers that prevent countries from properly addressing viral hepatitis — a pandemic that will kill 1.4 million people this year — as a global public health threat.

Our catalytic funding will speed the elimination of viral hepatitis by supporting the development of sustainable strategic plans at the national and sub-national level to guide effective program implementation; by showing how countries can optimize their human and financial resources within health budgets; by increasing the availability of country-specific data that inform where and how to intervene most efficiently and effectively; and, by building health system capacity to deliver quality hepatitis prevention and treatment services.

EndHep2030’s catalytic funding will be the spark that sets this historic effort in motion. MORE


Highly Motivated

More than 10% of Mongolia’s three million people are living with chronic hepatitis infection. The chances of a mother with viral hepatitis giving birth to an infected baby who develops life-long infection can be as high as 85%.

Fortunately, though heavily burdened by the disease, Mongolia has become a champion in the fight against it. In the first year of its Healthy Liver Program, more than 350,000 people were tested, and over 70% of those diagnosed with hepatitis were provided with treatment that is life-saving and prevents infection to others.

The means to prevent and cure the disease exist now. All we need is the will — and commitment — to make it happen.

Latest News

09.24.2018 / Business Today

Scientists create “golden eggs” that can treat cancer, hepatitis.

Japanese scientists at the Biomedical Research Institute at the National Institute of Advanced Industrial Science and Technology have created hens that can lay “golden eggs” containing a protein used to treat cancer and hepatitis. These scientists used new genome editing technology to create the hens that can lay multi-million pound golden eggs with high quantities of human interferon beta at a low cost.